The global pharmaceutical industry experienced a 25% decline in the number of artificial intelligence-related patent applications in Q3 2024 compared with the previous quarter. The total number of artificial intelligence-related grants dropped by 11% in Q3 2024, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q3 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of artificial intelligence-related patent applications in the pharmaceutical industry was 194 in Q3 2024, versus 257 in the prior quarter.
The top five companies accounted for 10% of patenting activity
Analysis of patenting activity by companies shows that Stanford University filed the most artificial intelligence patents within the pharmaceutical industry in Q3 2024. The company filed 5 artificial intelligence-related patents in the quarter, compared with 7 in the previous quarter. It was followed by Yiwu China Commodity City Holdings with 4 artificial intelligence patent filings, Shimadzu (4 filings), and Massachusetts Institute of Technology (3 filings) in Q3 2024.
Patenting activity was driven by the US with a 35% share of total patent filings
The largest share of artificial intelligence related patent filings in the pharmaceutical industry in Q3 2024 was in the US with 35%, followed by China (20%) and Japan (6%). The share represented by the US was 8% higher than the 27% share it accounted for in Q2 2024.
For further understanding of GlobalData's Pharma: Patents Trends Q3 2024, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.